1. Introduction {#sec1}
===============

Myocardial revascularization by timely percutaneous coronary intervention (PCI) or thrombolytic therapy was the most effective therapeutic approach for saving the endangered myocardium in acute myocardial infarction. Subsequent ischemia/reperfusion (I/R) damage inevitably caused substantial loss of myocytes and thus aggravated cardiac dysfunction \[[@B1], [@B2]\]. To date, myocardial I/R injury had increasingly become a crucial issue in a clinical practice, which attracted extensive attentions of researchers. However, there was still no adjunctive pharmacologic intervention targeting myocardial reperfusion injury due to the intricate molecular and cellular mechanisms \[[@B3]\]. In current, emerging evidence suggested the involvement of apoptosis, platelet activation, autophagy dysfunction, or inflammatory response \[[@B4]\], especially excessive free radical generation in the pathophysiological process of myocardial I/R injury \[[@B5]\].

Accumulating evidence had demonstrated that melatonin, an important circadian hormone produced in the pineal gland, exerts cardioprotective function against a wide variety of pathologic stimuli \[[@B6]\]. It had also reported that patients who suffered from acute myocardial infarction and sudden cardiac death were associated with a profound lower melatonin level \[[@B7]\]. Notably, as a key factor in regulating the circadian rhythm, it may possibly account for the increased frequency of cardiovascular events in the early morning \[[@B8]\]. Numerous studies had verified the role of melatonin in alleviating the ischemia-reperfusion injury and explored the potential underlying mechanisms, which mainly focused on its powerful capacity of free radical scavenging \[[@B9]--[@B11]\]. Meanwhile, other researchers also found that melatonin treatment abrogated ischemia-reperfusion-induced myocardial damage by hindering the migration of neutrophil, increasing the expression of antioxidant enzymes, along with antiadrenergic actions \[[@B12]--[@B14]\]. This evidence further emphasized the importance of melatonin implicated in the pathogenesis of cardiac attack post myocardial I/R injury. Nonetheless, the precise biological mechanisms by which melatonin exerted its protective properties were far from being clear and thus resulted in a huge gap between experimental studies and clinical application.

Therefore, our present meta-analysis is aimed at assessing the favorable effect of melatonin in alleviating myocardial I/R injury and summarizing potential molecular and cellular mechanisms from current available evidence of animal studies.

2. Methods {#sec2}
==========

2.1. Search Strategy {#sec2.1}
--------------------

We conducted a literature search in PubMed, MEDLINE, Embase, and Cochrane Database from the inception to December 2018 for potentially relevant articles reporting the cardioprotection of melatonin in myocardial I/R injury. The search terms are "myocardial ischemia/reperfusion injury" OR "myocardial I/R injury" OR "myocardial ischemia-reperfusion injury" AND "melatonin". The language was not restricted to English. Manual review of meeting abstracts, comments, and review articles was undertaken for additional citations.

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

Studies were eligible for inclusion if they met the following criteria: (a) reporting infarct size, expressed as the percentage of infarct area over area at risk (AAR), (b) melatonin compared with vehicle treatment, (c) *in vivo* or *ex vivo* animal studies, and (d) without cardiovascular-related comorbidity (i.e., obesity, diabetes, or chronic intermittent condition). We excluded studies only investigating the melatonin-mediated cardioprotection *in vitro.*

2.3. Data Extraction {#sec2.3}
--------------------

Two investigators (Zhi-Jie Mao and Hui Lin) independently extracted the data sets related to baseline information of included studies (i.e., author, year, state, and sample size), characteristic feature of animals (i.e., species, strain, body weight, or age), and detailed therapeutic strategy (i.e., dosage, route, and timing of melatonin treatment), along with the methods for determining the infarct size of the heart post myocardial I/R injury.

2.4. Quality Assessment {#sec2.4}
-----------------------

The quality of included studies was assessed and scored by two investigators (Hui Lin and Fang-Yi Xiao) based on published criteria \[[@B15]\]. Peer-reviewed publication, random allocation to groups, blinded assessment of outcome, sample size calculation, compliance with animal welfare regulations, and a statement of a potential conflict of interest were scored as one point, respectively. Discrepancies were resolved by discussion with a third investigator (Zhou-Qing Huang).

2.5. Statistical Analysis {#sec2.5}
-------------------------

Continuous variables as the mean and standard deviation were used for this meta-analysis. The weighted mean difference (WMD) with the related 95% CIs was calculated using the DerSimonian and Laird random-effects approach for infarct size. Heterogeneity was evaluated by *Q* statistics and quantified using *I*^2^ statistics. Publication bias was visually assessed with a funnel plot and further detected by Begger\'s and Egger\'s tests. If significant heterogeneity (*p* \< 0.10) was found across the studies, sensitivity analysis achieved by removing each study in turn, *post hoc* subgroup analyses (i.e., species, study type, duration of reperfusion, and timing regimen of pretreatment), and univariable metaregressions (i.e., sample size, state, species, study type, route of administration, and duration of reperfusion, along with timing regimen of pretreatment) were proposed to explore the potential sources of heterogeneity. *p* \< 0.05 were considered statistically significant for all results but heterogeneity. Statistical analyses and graphs were done with STATA version 12.0 (STATA Corporation, College Station, TX, USA).

3. Results {#sec3}
==========

Our search identified 115 study reports, of which 80 were excluded after title and abstract screening. 20 articles were relevant for full-text review (online [Table 1](#tab1){ref-type="table"}), and 15 studies of 211 animals (108 in the melatonin treatment group and 103 in the control group) fulfilled the prespecified inclusion criteria and were finally retained for our meta-analysis ([Figure 1](#fig1){ref-type="fig"}). A comprehensive list of individual studies is shown in [Table 1](#tab1){ref-type="table"}. 11 studies established a conventional *in vivo* myocardial I/R injury model, whereas in 4 studies, *ex vivo* regional ischemia-reperfusion was induced by left coronary artery occlusion in the perfused heart with Langendorff mode. All the studies investigated the cardioprotective effect of melatonin by using rats (either Sprague-Dawley or Wistar) and mice (C57BL/6). Infarct size was determined with Evans blue/TTC double staining in most studies; fluorescent particles, methylene blue, or blue dye added with TTC was the substitute in the remaining 4 studies. Melatonin was administered orally or by intravenous or intraperitoneal injection, along with perfusion before myocardial I/R injury. Studies were reported between 2000 and 2018. Nine of 15 studies were conducted in China, 3 studies in South Africa, 2 studies in Turkey, and 1 study in France. The quality of included studies is assessed in [Table 2](#tab2){ref-type="table"}, with the majority of studies scoring from 2 to 4, indicating reliable data and low risk of bias. The molecular mechanism underlying the beneficial effect of melatonin in protecting the heart against myocardial I/R insult was sophisticated and diverse; it is summarized in [Table 3](#tab3){ref-type="table"}.

3.1. Infarct Size {#sec3.1}
-----------------

As presented in [Figure 2](#fig2){ref-type="fig"}, pretreatment with melatonin significantly reduced the infarct size in comparison with vehicle treatment (WMD: -20.45, 95% CI: -25.43 to -15.47, *p* \< 0.001). There was a significant amount of heterogeneity across the studies (*I*^2^ = 91.4%, *p* \< 0.001) ([Figure 3](#fig3){ref-type="fig"}). A symmetrical funnel plot followed with Begg\'s (*p* = 0.79) and Egger\'s (*p* = 0.711) tests reasonably excluded the presence of publication bias. Moreover, sensitivity analysis did not reveal any variation in the pooled estimate of WMD, supporting the robust effect in favor of melatonin treatment ([Table 4](#tab4){ref-type="table"}). Post hoc subgroup analyses performed to explore the source of heterogeneity among studies did not show significant results ([Table 5](#tab5){ref-type="table"}). Univariable metaregression failed to expose any significant correlation between study-level covariates, i.e., sample size, species, study type, state, route of administration, reperfusion duration, and timing regimen of pretreatment and the magnitude of WMD ([Table 6](#tab6){ref-type="table"}).

3.2. Cardiac Function {#sec3.2}
---------------------

Data on left ventricular EF was available by echocardiography in 7 out of 15 studies. Melatonin treatment was associated with significantly higher EF after myocardial I/R injury (WMD: 17.19, 95% CI: 11.08 to 23.29, *p* \< 0.001) ([Figure 4](#fig4){ref-type="fig"}), with high heterogeneity (I^2^ = 77.0%, *p* \< 0.001). FS was evaluated in 5 eligible studies; in accordant with EF, melatonin administration evidently increased FS (WMD: 14.18, 95% CI: 11.22 to 17.15, *p* \< 0.001) ([Figure 5](#fig5){ref-type="fig"}), with no significant heterogeneity (*I*^2^ = 3.5%, *p* = 0.387). Systematically removing each study also did not markedly affect the pooled WMD and related *p* value, respectively.

4. Discussion {#sec4}
=============

As far as we know, it was the first study to pool all available evidence and show the beneficial effect of melatonin in protecting the myocardium against ischemia/reperfusion damage. A previous meta-analysis confirmed the markedly neuroprotective effect of melatonin in improving the outcomes in the animal models of focal cerebral ischemia \[[@B16]\], while our meta-analysis demonstrated that melatonin treatment was associated with a significantly reduced infarct size in the context of myocardial I/R injury. Accordingly, similar improvement was also noted in left ventricular EF and FS, which indicated the critical role of melatonin in attenuating the reperfusion injury and subsequent cardiac dysfunction.

Although acute coronary artery occlusion was widely recognized as the most important determinant for cardiomyocyte death from ischemic heart disease, substantial evidence indicated that reperfusion injury secondary to restored blood flow accounted for nearly half of infarct size, finally exacerbating ventricular dysfunction during ST-segment elevation myocardial infarction \[[@B1], [@B2]\]. In the past decades, the pathogenesis of myocardial I/R injury was deeply investigated, e.g., excessive generation of reactive oxygen species, calcium overload, mitochondrial permeability transition pore opening, mitochondrial dysfunction, platelet aggregation, and apoptosis were partially responsible for the cardiomyocyte loss under reperfusion damage \[[@B17], [@B18]\]. Additionally, autophagy which recycled the impaired organelles, e.g., mitochondria or misfolded protein, for cardiac cellular homeostasis and ATP supply was implicated in the pathological process of myocardial I/R injury \[[@B4], [@B19]\]. Notably, either excessive or insufficient autophagy was associated with increased cell death, thus resulting in an enlarged infarct area and compromised ventricular contraction. Moreover, both *in vivo* and *in vitro* evidence demonstrated that plasma exosomes (particularly rich in miRNA or proteins) exerted cardioprotection against severe injury during ischemia/reperfusion mediated by activation of the HSP70/TLR4 communication axis \[[@B20]\]. Prior studies had identified that miRNAs were important targets for regulating myocardial reperfusion damage \[[@B21], [@B22]\]. More recently, lncRNAs had also been extensively investigated in the context of ischemic heart disease, especially as key mediators of acute myocardial I/R injury and also targets for cardioprotection \[[@B23]\]. Emerging evidence showed a mutual interaction between lncRNAs and miRNAs; lncRNAs were demonstrated as a sponge to inhibit the expression of miRNA, regulating the activity of miRNA, along with competing for mRNAs. Among the aforementioned pathogenesis of myocardial tissue damage during reperfusion insult, oxidative stress was the most well-established basic mechanism and characterized by severe imbalance between exaggerated ROS generation and corresponding antioxidant defense systems \[[@B5]\]. In the context of myocardial I/R injury, upregulated expression of NOXs in infiltrated neutrophils, eNOS uncoupling, and impaired mitochondria were the main source of ROS which further resulted in mitochondrial damage, triggering the caspase-dependent apoptotic pathway. Moreover, ROS was considered to be a major determinant in adverse ventricular remodeling via promoting interstitial fibrosis, deposition of collagen, cardiomyocyte hypertrophy, or induction of cell death \[[@B24]\]. It thus provided the rationale for developing therapeutic options against the vicious cycle of ROS synthesis and degradation. Nonetheless, effective interventions which could translate into clinical application remained lacking due to the conflicting data between experimental evidence and human clinical trials.

Melatonin, a key factor in controlling the circadian rhythm, had been demonstrated to play a pivotal role in various cardiovascular diseases including heart failure, atherosclerosis, myocardial infarction, hypertension, vascular endothelial dysfunction, or cardiotoxicity \[[@B25]\]. Substantial evidence showed that the cardioprotective action of melatonin was closely related to its antioxidant properties \[[@B26]\]. Meanwhile, recent studies indicated a profound beneficial effect of melatonin against oxidative stress and retarding the deterioration of cardiac function after myocardial I/R injury \[[@B10], [@B11]\]. Early in 2004, Sahna and colleagues found that melatonin administration significantly inhibited the expression of MDA and increased the GSH levels in a mouse myocardial I/R model \[[@B27]\]. Subsequently, Yu et al. showed a significant antioxidative stress effect in retarding the surge of NADPH oxidase (gp91^phox^) and MDA, accompanied by a restored level of SOD after reperfusion damage \[[@B28]\]. Recently, experimental researches further confirmed the role of melatonin as a powerful free radical scavenger, which contributed to preserved contractile function and reduced infarct area in the context of myocardial I/R insult \[[@B10]\]. Unsurprisingly, this meta-analysis presented the outstanding therapeutic properties of melatonin in attenuating the infarct size post I/R injury, which therefore may account for the improved cardiac function (i.e., EF and FS). However, convincing experimental data outlined the other cell biological actions implicated in melatonin\'s beneficial effects, for instance, anti-inflammation, antiapoptosis, and regulating mitochondrial function and autophagy, as well as modulating the metabolic process \[[@B9], [@B29], [@B30]\]. Moreover, Genade et al. indicated that the antiadrenergic effects mediated by NO and RISK pathway were also responsible for melatonin-induced cardioprotection against I/R damage \[[@B12]\]. Noteworthily, further mechanistic explorations found that there were various crucial downstream signaling pathways underlying the favorable effects of melatonin in the treatment of cardiovascular disease. Previous studies reported that the activation of the Nrf2 pathway is a key antioxidant mediator in melatonin treatment by enhancing the expression of HO-1, GAPDH, or GSH S-transferase a-1 (GST-a1). In addition, the ROS-scavenging system was activated by melatonin through Notch1/Hes1/Akt pathways which maintained the intracellular redox homeostasis \[[@B31]\]. Furthermore, there was also a direct corelationship between the JAK/STAT signaling pathway and melatonin receptor, which facilitated the antioxidative stress processes in the reperfused heart \[[@B25]\]. Pretreatment with melatonin by Yang et al. showed increased expression of SOD and suppressed generation of MDA and mitochondrial H~2~O~2~ by activation of JAK2/STAT3 signaling cascade in perfused isolated hearts, whereas it was abolished in the presence of AG490 (JAK2/STAT3 inhibitor) or genetic modulation (JAK2 siRNA) \[[@B32]\]. Meanwhile, activation of JAK2/STAT3 provided additional antiapoptotic effects by regulating the expression of Bcl-2/Bax. Importantly, melatonin was also implicated in the autophagic process during the reperfusion damage via the AMPK/mTOR signaling pathway \[[@B33]\]. Recent studies highlighted the decisive role of PPAR*γ*/FUNDC1 and AMPK*α* axis which modulated the function and structure of mitochondria (i.e., mitophagy, mitochondrial fission, HK2-VDAC1 interaction, or mitochondria-induced apoptotic pathway) in the therapeutic action of melatonin \[[@B13]\]. Overall evidence from basic researches showed that melatonin treatment was a promising cardioprotective strategy in the context of myocardial I/R injury.

However, the published data on the efficacy of melatonin in STEMI patients receiving early revascularization remained lacking. A nested case-control study found that low melatonin secretion was expressively associated with a higher risk of myocardial infarction in women with increased BMI \[[@B34]\]. Unexpectedly, the MARIA trial demonstrated that melatonin administration did not reduce the infarct size; contrariwise, it may aggravate ventricular remodeling \[[@B35]\]. Nevertheless, subsequent post hoc analysis revealed that early treatment with melatonin resulted in less infarct area in patients suffering from reperfusion damage \[[@B36]\]. In addition, Dwaich et al. found a dose-dependent protective effect of melatonin in suppressing the pathological process during the CABG \[[@B37]\]. Thus, the different dosages and duration of ischemia among the clinical studies may be responsible for the conflicting results. Divergent plasma concentration of melatonin, mass of salvage myocardium after I/R insult, and even the distinct activated signaling cascades in different pathological phases collectively weakened the beneficial effect of melatonin \[[@B38], [@B39]\]. Meanwhile, the timing and form of drug delivery and approaches for infarct size determination may also have impact on the outcomes. Altogether, so far, it was quite challenging to translate the favorable effects of melatonin into the clinical setting. More well-designed RCTs were pressing need to further identify the cardioprotective role of melatonin in myocardial I/R injury.

4.1. Limitation {#sec4.1}
---------------

First, the results of our meta-analysis were based on study-level data rather than individual animal-level data which impeded further subgroup analysis, i.e., detailed dosage of melatonin treatment, precise age, or body weight of each rodent that may have an impact on pharmacokinetic or pharmacodynamic profile of melatonin intake, along with laboratory mouse or rat strains. Second, there was no standard regimen about the timing of either ischemic/reperfusion duration or melatonin precondition. For instance, the huge difference of time interval for melatonin pretreatment (ranged from 10 minutes to 4 weeks) may also confuse the most optimal administration time of melatonin, despite the remarkable consistency across all the included studies. Third, significant high heterogeneity in this work may inevitably affect the interpretation of results; however, robust data evidenced by both sensitivity analysis and stratified analysis verified the benefits and reliability of melatonin treatment in ameliorating the infarct size post reperfusion injury. In accordant with this, metaregression also failed to reveal any influence of prespecified covariates on pooled estimates of infarct size. Fourth, it was regrettable that overall included studies reported the instant efficacy of melatonin in improving infarct size and inhibiting subsequent cardiac dysfunction, but whether pretreatment with melatonin could maintain its cardioprotective effect for a long while was unknown and needed further exploration. Finally, there was a critical weakness in our work that the evidence of favorable effects with melatonin precondition was not confirmed by large animal studies (more relevant to humans). Therefore, there was pressing need for further investigations in large animals before the human clinical trials.

5. Conclusion {#sec5}
=============

Melatonin treatment was associated with a significant improvement in infarct size and cardiac function in rodent hearts post I/R injury. It provided the rationale for clinical application of melatonin combined with immediate coronary revascularization in acute myocardial infarction patients.
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###### 

Baseline characteristics of studies, animals, and melatonin treatment.

  Author                           Year   State          Species         Weight/year   Type of I/R   Anesthetic                Sample size   I/R duration   Infarct size/AAR   Melatonin treatment         
  -------------------------------- ------ -------------- --------------- ------------- ------------- ------------------------- ------------- -------------- ------------------ --------------------------- ---------------------------------------
  Chen et al.\[[@B31]\]            2018   China          Rats, SD        250-300 g     In vivo       Chloral hydrate           6             6              30 min/2 h         Evans blue/TTC              20 mg/kg, i.p., 12 h before I/R
  Zhou et al.\[[@B13]\]            2017   China          Mice, C57BL/6   20-25 g       In vivo       Pentobarbital sodium      6             6              120 min/4 h        Evans blue/TTC              20 mg/kg, i.p., 12 h before I/R
  Zhai et al. \[[@B10]\]           2017   China          Mice, C57BL/6   20-22 g       In vivo       2% isoflurane             8             8              30 min/24 h        Evans blue/TTC              20 mg/kg, i.p., 10 min before I/R
  Zhou et al. \[[@B17]\]           2017   China          Mice, C57BL/6   20-25 g       In vivo       NA                        6             6              30 min/2 h         Evans blue/TTC              20 mg/kg, i.p., 12 h before I/R
  He et al. \[[@B9]\]              2016   China          Mice, C57BL/6   NA            In vivo       2% isoflurane             8             8              30 min/24 h        Evans blue/TTC              150 *μ*g/kg, i.p., 30 min before I/R
  Yu et al. \[[@B29]\]             2015   China          Rats, SD        200-250 g     In vivo       3% pentobarbital sodium   8             8              30 min/6 h         Evans blue/TTC              10 mg/kg, p.o., 4 weeks before I/R
  Yu et al. \[[@B26]\]             2014   China          Rats, SD        200-220 g     In vivo       3% pentobarbital sodium   6             6              30 min/6 h         Evans blue/TTC              10 mg/kg, i.p., 7 days before I/R
  Chen et al. \[[@B27]\]           2009   China          Mice, C57BL/6   4-5 months    In vivo       Tribromoethanol           6             6              50 min/4 h         Evans blue/TTC              150 *μ*g/kg, i.p., 30 min before I/R
  Genade et al. \[[@B12]\]         2008   South Africa   Rats, Wistar    230--280 g    Ex vivo       Pentobarbital sodium      7             11             35 min/2 h         Evans blue/TTC              50 *μ*M, perfusion, 10 min before I/R
  Lochner et al. \[[@B24]\]        2006   South Africa   Rats, Wistar    220--250 g    Ex vivo       Pentobarbital sodium      6             6              35 min/2 h         Evans blue/TTC              50 *μ*M, perfusion, 10 min before I/R
  Sahna et al. \[[@B25]\]          2005   Turkey         Rats, Wistar    250-300 g     In vivo       Urethane                  8             8              30 min/2 h         Fluorescent particles/TTC   10 mg/kg, i.v., 10 min before I/R
  Sahna et al. \[[@B11]\]          2002   Turkey         Rats, Wistar    150-200 g     In vivo       Urethane                  8             8              30 min/2 h         Fluorescent particles/TTC   4 mg/kg, i.v., 10 min before I/R
  Lee et al. \[[@B14]\]            2002   China          Rats, SD        250--300 g    In vivo       Pentobarbital sodium      6             6              45 min/1 h         Methylene blue/TTC          5 mg/kg, i.v., 10 min before I/R
  Lagneux et al. \[[@B35]\]        2000   France         Rats, Wistar    280--350 g    Ex vivo       Sodium pentobarbital      6             6              30 min/2 h         Blue dye/TTC                10 mg/kg, i.p., 30 min before I/R
  Nduhirabandi et al. \[[@B28]\]   2010   South Africa   Rats, Wistar    180-220 g     Ex vivo       Sodium pentobarbital      8             9              40 min/2 h         Evans blue/TTC              4 mg/kg, p.o., 16 weeks before I/R

SD: Sprague-Dawley rats; M: male; i.p.: intraperitoneal injection; i.v.: intravenous injection; p.o.: orally treated; I/R: ischemia/reperfusion injury; TTC: triphenyltetrazolium chloride.

###### 

The quality of included studies.

  Studies               Year   A   B   C   D   E   F   Score
  --------------------- ------ --- --- --- --- --- --- -------
  Chen et al.           2018   Y   Y   N   N   Y   Y   4
  Zhou et al.           2017   Y   N   N   N   Y   Y   3
  Zhai et al.           2017   Y   Y   N   N   Y   Y   4
  Zhou et al.           2017   Y   N   N   N   Y   Y   3
  He et al.             2016   Y   N   N   N   Y   Y   3
  Yu et al.             2015   Y   Y   N   N   Y   Y   3
  Yu et al.             2014   Y   Y   N   N   Y   Y   4
  Chen et al.           2009   Y   N   N   N   Y   Y   3
  Genade et al.         2008   Y   N   N   N   Y   N   2
  Lochner et al.        2006   Y   N   N   N   Y   N   2
  Sahna et al.          2005   Y   N   N   N   Y   N   2
  Sahna et al.          2002   Y   Y   N   N   Y   Y   4
  Lee et al.            2002   Y   Y   N   N   Y   Y   4
  Lagneux et al.        2000   Y   N   N   N   Y   N   2
  Nduhirabandi et al.   2010   Y   N   N   N   Y   Y   3

A: peer-reviewed publication; B: random allocation to groups; C: blinded assessment of outcomes; D: sample size calculation; E: compliance with animal welfare regulations; F: a statement of a potential conflict of interest; Y: yes; N: no.

###### 

The molecular and cellular mechanisms underlying the cardioprotection of melatonin treatment in myocardial I/R injury.

  Studies               Year   Proposed mechanisms
  --------------------- ------ -------------------------------------------------------------------------------------------------------------------------------------
  Chen et al.           2018   Inhibit autophagy via AMPK/mTOR signaling pathway
  Zhou et al.           2017   Attenuate FUNDC1-required mitophagy, inflammation, improve microvascular function via regulating the expression of platelet PPAR*γ*
  Zhai et al.           2017   Antioxidative stress, antiapoptosis through activation of SIRT3 signaling pathway
  Zhou et al.           2017   Regulate mitochondrial fission, mitophagy, mPTP opening, and HK2-VDAC1 interaction
  He et al.             2016   Restore autophagy function, suppress oxidative stress and apoptosis through nuclear receptor ROR*α*
  Yu et al.             2015   Notch1/Hes1 signaling and Pten/Akt signaling underlie the antioxidative stress and antiapoptosis effect
  Yu et al.             2014   Reduce apoptosis and oxidative damage via SIRT1 signaling
  Chen et al.           2009   Attenuate apoptosis independent of Gpx1
  Genade et al.         2008   Antiadrenergic actions mediated by NO and PKC signaling, PKB/Akt activation, and p38MAPK signaling involved in the cardioprotection
  Lochner et al.        2006   NA
  Sahna et al.          2004   Attenuate oxidative stress (reduce MDA and restore GSH level)
  Sahna et al.          2002   NA
  Lee et al.            2002   Antioxidant activity, inhibit neutrophil infiltration
  Lagneux et al.        2000   NA
  Nduhirabandi et al.   2010   Prevent metabolic abnormality via modulating insulin release and PKB/Akt and ERK 1/2 signaling

###### 

Sensitivity analysis.

  Study omitted         Year     WMD              95% CI           *p* value   Heterogeneity
  --------------------- -------- ---------------- ---------------- ----------- -------------------------------
  Chen et al.           2018     -20.00           -25.29, -14.70   \<0.001     *I* ^2^ = 91.6%, *p* \< 0.001
  Zhou et al.           2017     -19.76           -24.80, -14.71   \<0.001     *I* ^2^ = 91.8%, *p* \< 0.001
  Zhai et al.           2017     -20.83           -26.14, -15.51   \<0.001     *I* ^2^ = 91.9%, *p* \< 0.001
  Zhou et al.           2017     -18.80           -23.01, -14.59   \<0.001     *I* ^2^ = 86.2%, *p* \< 0.001
  He et al.             2016     -21.30           -26.40, -16.21   \<0.001     *I* ^2^ = 90.5%, *p* \< 0.001
  Yu et al.             2015     -20.80           -26.00, -15.59   \<0.001     *I* ^2^ = 91.9%, *p* \< 0.001
  Yu et al.             2014     -20.74           -25.92, -15.52   \<0.001     *I* ^2^ = 92.0%, *p* \< 0.001
  Chen et al.           2009     -20.32           -25.45, -15.19   \<0.001     *I* ^2^ = 92.0%, *p* \< 0.001
  Genade et al.         2008     -20.75           -26.40, -15.10   \<0.001     *I* ^2^ = 91.8%, *p* \< 0.001
  Lochner et al.        2006     -19.61           -24.65, -14.58   \<0.001     *I* ^2^ = 90.3%, *p* \< 0.001
  Sahna et al.          2005     -20.85           -26.08, -15.62   \<0.001     *I* ^2^ = 91.9%, *p* \< 0.001
  Sahna et al.          2002     -21.21           -26.32, -16.10   \<0.001     *I* ^2^ = 91.8%, *p* \< 0.001
  Lee et al.            2002     -19.70           -24.48, -14.56   \<0.001     *I* ^2^ = 91.6%, *p* \< 0.001
  Lagneux et al.        2000     -21.32           -26.42, -16.23   \<0.001     *I* ^2^ = 90.6%, *p* \< 0.001
  Nduhirabandi et al.   2010     -20.72           -26.29, -15.14   \<0.001     *I* ^2^ = 91.9%, *p* \< 0.001
  Overall               -20.45   -25.43, -15.47   \<0.001          \<0.001     

###### 

*Post hoc* subgroup analysis of pooled estimates of infarct size.

  Pooled estimates                 No. of studies   WMD      95% CI           *p* value   Heterogeneity
  -------------------------------- ---------------- -------- ---------------- ----------- -------------------------------
  Species                                                                                 
   Rats                            10               -19.06   -23.87, -14.25   \<0.001     *I* ^2^ = 87.3%, *p* \< 0.001
   Mice                            5                -24.83   -39.20, -10.46   \<0.001     *I* ^2^ = 95.6%, *p* \< 0.001
  Study type                                                                              
   *In vivo*                       11               -21.27   -28.50, -14.04   \<0.001     *I* ^2^ = 90.3%, *p* \< 0.001
   *Ex vivo*                       4                -18.76   -26.22, -11.29   \<0.001     *I* ^2^ = 93.8%, *p* \< 0.001
  Reperfusion duration                                                                    
   ≥6 h                            11               -22.84   -28.89, -16.78   \<0.001     *I* ^2^ = 92.3%, *p* \< 0.001
   \<6 h                           4                -13.04   -16.40, -9.68    \<0.001     *I* ^2^ = 15.0%, *p* = 0.317
  Timing regimen of pretreatment                                                          
   \>60 min                        6                -24.89   -33.87, -15.92   \<0.001     *I* ^2^ = 91.6%, *p* \< 0.001
   ≤60 min                         9                -17.68   -23.45, -11.92   \<0.001     *I* ^2^ = 89.8%, *p* \< 0.001
  Overall                          15               -20.45   -25.43, -15.47   \<0.001     *I* ^2^ = 91.4%, *p* \< 0.001

###### 

Metaregression of pooled estimates of infarct size.

  Covariates                       Infarct size                          
  -------------------------------- -------------- ---------------------- -------
  Sample size                      2.360435       0.3001453, 4.420724    0.208
  Species                          -5.111393      -17.30782, 7.085032    0.382
  Study type                       2.456891       -9.851739, 14.76552    0.673
  State                            4.689403       -0.6606213, 10.03943   0.081
  Route of administration          0.5208883      -4.255456, 5.297233    0.817
  Duration of reperfusion          0.2287274      -3.982206, 4.439661    0.908
  Timing regimen of pretreatment   3.072655       -0.4711795, 6.61649    0.084

[^1]: Academic Editor: Danina Muntean
